Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Uni-Bio Science Group Ltd. ( (HK:0690) ) has shared an announcement.
Uni-Bio Science Group Ltd. announced that its new ophthalmology product, Diquafosol Sodium Eye Drops, has received marketing approval from the China National Medical Products Administration. This approval strengthens the company’s ophthalmology drug pipeline and offers a new treatment option for dry eye syndrome, a condition affecting over 360 million people in China. The product utilizes advanced Blow-Fill-Seal technology and preservative-free packaging, enhancing quality and convenience. The company has also secured strategic partnerships and expanded its sales channels, positioning itself for rapid market penetration and competitiveness in the growing ophthalmic market.
More about Uni-Bio Science Group Ltd.
Uni-Bio Science Group Ltd. operates in the pharmaceutical industry, focusing on ophthalmology drugs. The company develops innovative treatments for eye-related conditions, with a market focus on China.
Average Trading Volume: 9,852,236
Technical Sentiment Signal: Buy
Current Market Cap: HK$458.7M
See more insights into 0690 stock on TipRanks’ Stock Analysis page.